Genitourinary (Issue 3)

Charles Ryan, MD, Professor of Clinical Medicine and Urology, Department of Medicine, Program Leader, Genitourinary Medical Oncology at the Helen Diller Family Comprehensive Cancer at the Univeristy of California San Francisco, discusses abiraterone acetate in elderly chemotherapy naive patients with metastatic castration resistant prostate cancer (mCRPC).

Treatment with unilateral high-intensity focused ultrasound led to eradication of all clinically significant cancer in the treated lobe for 94% of patients with early prostate cancer.

Men with metastatic castration-resistant prostate cancer experienced significant reductions in bone pain and improvements in quality of life when treated with the combination of radium-223 and abiraterone.

With a little help from a negotiation expert, prostate cancer specialists persuaded significantly more men with low-risk prostate cancer to enroll in active surveillance, results of an observational study showed.

A high rate of PSA testing in the control arm of the Prostate, Lung, Colorectal, and Ovary screening trial made meaningful comparisons with the intervention group impossible, according to a new analysis of data from the landmark trial.

A. Oliver Sartor, MD, Medical Director of Tulane Cancer Center, explains why primary care physicians and oncologists/urologists have differences of opinion when it comes to prostate-specific antigen (PSA) testing.

Abiraterone acetate in combination with low-dose prednisone showed a low overall incidence of corticosteroid-associated adverse events that were not significantly different compared with prednisone alone for patients with metastatic castration-resistant prostate cancer.

Neal Shore, MD, medical director of Carolina Urologic Research Center, discusses corticosteroid-associated adverse events with low-dose prednisone given with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC).